Immunic (STU:10VA) Accounts Payable & Accrued Expense : €17.09 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Immunic Accounts Payable & Accrued Expense?

Immunic's quarterly accounts payable & accrued expense increased from Sep. 2023 (€14.81 Mil) to Dec. 2023 (€20.45 Mil) but then declined from Dec. 2023 (€20.45 Mil) to Mar. 2024 (€17.09 Mil).

Immunic's annual accounts payable & accrued expense increased from Dec. 2021 (€8.98 Mil) to Dec. 2022 (€10.74 Mil) and increased from Dec. 2022 (€10.74 Mil) to Dec. 2023 (€20.45 Mil).

Immunic Accounts Payable & Accrued Expense Historical Data

The historical data trend for Immunic's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Accounts Payable & Accrued Expense Chart

Immunic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.15

6.05

8.98

10.74

20.45

Immunic Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															14.09	15.32	14.81	20.45	17.09

Immunic Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Immunic (STU:10VA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

IMUX:USA 10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines